These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25985576)

  • 1. Association of the use of amlodipine with clopidogrel response in Chinese patients undergoing percutaneous coronary intervention.
    Liu XQ; Lin S; Qiu LL; Lin L; Zhao YY; Xu HM; Zhang J; Zou JJ
    Pharmazie; 2014 Nov; 69(11):814-7. PubMed ID: 25985576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of CYP2C19 loss-of-function variants on the antiplatelet effects and cardiovascular events in clopidogrel-treated Chinese patients undergoing percutaneous coronary intervention.
    Zou JJ; Xie HG; Chen SL; Tan J; Lin L; Zhao YY; Xu HM; Lin S; Zhang J; Wang GJ
    Eur J Clin Pharmacol; 2013 Apr; 69(4):771-7. PubMed ID: 23001453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efffect of the ABCC3 -211C/T polymorphism on clopidogrel responsiveness in patients with percutaneous coronary intervention.
    Zou JJ; Fan HW; Chen SL; Tan J; He BS; Xie HG
    Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):504-9. PubMed ID: 23692149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
    Harmsze AM; Robijns K; van Werkum JW; Breet NJ; Hackeng CM; Ten Berg JM; Ruven HJ; Klungel OH; de Boer A; Deneer VH
    Thromb Haemost; 2010 May; 103(5):920-5. PubMed ID: 20352154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
    Yang J; Zhao HD; Tan J; Ding YL; Gu ZQ; Zou JJ
    Pharmazie; 2013 Mar; 68(3):183-6. PubMed ID: 23556336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
    Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
    EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel.
    Siller-Matula JM; Lang I; Christ G; Jilma B
    J Am Coll Cardiol; 2008 Nov; 52(19):1557-63. PubMed ID: 19007592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CES1A -816C as a genetic marker to predict greater platelet clopidogrel response in patients with percutaneous coronary intervention.
    Zou JJ; Chen SL; Fan HW; Tan J; He BS; Xie HG
    J Cardiovasc Pharmacol; 2014 Feb; 63(2):178-83. PubMed ID: 24508947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients.
    Yang J; Zhou JS; Tan J; He BS; Zou JJ
    Pharmazie; 2012 Dec; 67(12):1026-9. PubMed ID: 23346768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
    Tang N; Yin S; Sun Z; Xu X; Qin J
    Scand J Clin Lab Invest; 2015 May; 75(3):223-9. PubMed ID: 25594796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.
    Sibbing D; Koch W; Massberg S; Byrne RA; Mehilli J; Schulz S; Mayer K; Bernlochner I; Schömig A; Kastrati A
    Eur Heart J; 2011 Jul; 32(13):1605-13. PubMed ID: 21527445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han.
    Wang JY; Zhang YJ; Li H; Hu XL; Li MP; Song PY; Ma QL; Peng LM; Chen XP
    Gene; 2018 Dec; 678():226-232. PubMed ID: 30096456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel.
    Tang XF; Han YL; Zhang JH; Wang J; Zhang Y; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Chin Med J (Engl); 2015 Mar; 128(6):774-9. PubMed ID: 25758271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.
    Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
    Heart; 2010 Feb; 96(3):186-9. PubMed ID: 19687016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting.
    Sibbing D; Morath T; Braun S; Stegherr J; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    Thromb Haemost; 2010 Jan; 103(1):151-9. PubMed ID: 20062919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.
    Sibbing D; Braun S; Morath T; Mehilli J; Vogt W; Schömig A; Kastrati A; von Beckerath N
    J Am Coll Cardiol; 2009 Mar; 53(10):849-56. PubMed ID: 19264241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of clopidogrel and calcium channel blockers and risk of major adverse cardiovascular events.
    Schmidt M; Johansen MB; Robertson DJ; Maeng M; Kaltoft A; Jensen LO; Tilsted HH; Bøtker HE; Sørensen HT; Baron JA
    Eur J Clin Invest; 2012 Mar; 42(3):266-74. PubMed ID: 21834799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of impact of calcium-channel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting.
    Sarafoff N; Neumann L; Morath T; Bernlochner I; Mehilli J; Schömig A; Kastrati A; Sibbing D
    Am Heart J; 2011 Mar; 161(3):605-10. PubMed ID: 21392618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble P-selectin level correlates with acetylsalicylic acid but not with clopidogrel response in patients with stable coronary artery disease after a percutaneous coronary intervention.
    Kaufmann J; Wellnhofer E; Kappert K; Urban D; Meyborg H; Hauptmann T; Müller A; Meixner M; Graf K; Fleck E; Stawowy P
    Coron Artery Dis; 2013 Jun; 24(4):312-20. PubMed ID: 23549485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.